Imaging biomarkers in corticobasal syndrome
Official title: Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome
Run by Mayo Clinic · NCT07000851 · Data updated 2026-11-12
We will use brain imaging and blood tests to see if inflammation is linked to white-matter damage in people with corticobasal syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | June 25, 2025 |
| Main results expected | March 30, 2030 |
| Study ends | March 30, 2031 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT07000851 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who meet possible or probable corticobasal syndrome criteria, can undergo MRI and PET scanning, are not pregnant, are not taking daily anti-inflammatory or recent immunosuppressive therapy, and do not have a progranulin mutation are ideal candidates.
✕Probably not a fit
People with MRI contraindications, active generalized inflammatory conditions, recent anti-inflammatory or immunosuppressive treatment, prior anti-amyloid therapy, or progranulin mutations may not receive benefit from this imaging-focused study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Corticobasal syndrome is a neurodegenerative disorder marked by asymmetric motor symptoms and cognitive and behavioral changes. This observational project tests whether neuroinflammation and white-matter microstructure changes are related in people with CBS using PET, advanced MRI, and blood biomarkers. Investigators will use the PET ligand 11C-ER176 to map inflammation, NODDI diffusion imaging to measure white-matter microstructure, and plasma measures such as neurofilament light and GFAP alongside A and tau PET to subgroup patients. Results will be compared to typical amnestic AD cases and healthy controls, and molecular pathology data will be used where available.
Why it matters
Potential benefit: If successful, the work could identify inflammatory and white-matter biomarkers that improve diagnosis and help target treatments for subgroups of CBS patients.
How similar studies have gone: Related PET inflammation imaging, diffusion MRI (NODDI), and plasma biomarker approaches have provided useful insights in Alzheimer's disease and other tauopathies, although applying 11C-ER176 specifically in CBS is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Meet possible or probable CBS criteria Exclusion Criteria: * Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc) * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome * Subjects will be excluded if they have a mutation in the progranulin gene * Subjects will excluded if they have received anti-Aβ therapy * Women who are pregnant will be excluded * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc) * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning
Where it's running
-
Mayo Clinic
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Jennifer Whitwell, Ph.D. — Mayo Clinic
- Study coordinator: Megan J Meyer, M.B.A.
- Email: meyer.megan6@mayo.edu
- Phone: 507-293-1164
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Genetic program for Progressive Supranuclear Palsy and related conditions
This study is collecting DNA from adults with Progressive Supranuclear Palsy and similar conditions to see how genetics might help improve diagnosis and care for patients.
-
Using scrambler therapy to treat pain in corticobasal syndrome
This study is testing if scrambler therapy can help reduce nerve pain in people with corticobasal syndrome.
-
Wellness program for PSP and CBD: a virtual multimodal lifestyle approach
This study tests a virtual 8-week program combining chair yoga, voice strengthening, and peer support to see if it improves emotional wellbeing and quality of life for adults with PSP or CBD and whether it eases caregiver burden.
-
Natural history of atypical parkinsonian syndromes: a multi-center observation
This study follows people with APS like MSA, DLB, PSP, and CBD to see how their symptoms and brain images change over time.
-
Using AI to improve the levodopa challenge test for Parkinson's disease diagnosis
This study is testing a new way to diagnose Parkinson's disease using artificial intelligence and video recordings to see if it can improve the accuracy of the levodopa challenge test.
-
Examining health services and quality of life in patients with atypical Parkinsonian syndromes
This study looks at how people with atypical Parkinsonian syndromes, like progressive supranuclear palsy and multiple system atrophy, use health services and how their quality of life is affected by having access to specialist clinics and support services.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.